One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Annals of the Rheumatic Diseases collection on glucocorticoids (2020–2023): novel insights and advances in therapyHandling editor
doi : 10.1136/ard-2023-224847
Improving the nosology of Long COVID: it is not so simpleHandling editor
doi : 10.1136/ard-2023-224844
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateHandling editor
doi : 10.1136/ard-2023-224762
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 updateHandling editor
doi : 10.1136/ard-2022-223764
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumaticaHandling editor
doi : 10.1136/ard-2022-223429
Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritisHandling editor
doi : 10.1136/ard-2023-224477
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
doi : 10.1136/ard-2023-224270
Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis
doi : 10.1136/ard-2023-224503
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study
doi : 10.1136/ard-2023-224343
Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database
doi : 10.1136/ard-2023-224472
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying
doi : 10.1136/ard-2023-224571
Global, regional and national temporal trends in prevalence for musculoskeletal disorders in women of childbearing age, 1990–2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019
doi : 10.1136/ard-2023-224530
Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot' collaboration
